Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,275,349 papers from all fields of science
Search
Sign In
Create Free Account
AC 7700
Known as:
AVE8062
, Combretastatin A4 Analogue AVE8062
, AC7700
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (1)
Serine
analogs & derivatives
Narrower (1)
ombrabulin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
Ya-Ting Ji
,
Yan-Na Liu
,
Zhaopeng Liu
Current Medicinal Chemistry
2015
Corpus ID: 10766831
Tumor vasculature is an important target in cancer treatment. Two distinct vasculartargeting therapeutic strategies are applied…
Expand
Review
2009
Review
2009
AVE8062: a new combretastatin derivative vascular disrupting agent
A. Delmonte
,
C. Sessa
Expert Opinion on Investigational Drugs
2009
Corpus ID: 7701391
Angiogenesis has an essential role in promoting and supporting tumor growth and it is an important therapeutic target. The tumor…
Expand
Highly Cited
2008
Highly Cited
2008
Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography
S. Lavisse
,
P. Lejeune
,
+9 authors
N. Lassau
Investigative Radiology
2008
Corpus ID: 23623670
Objectives:To evaluate the early tumor vasculature disrupting effects of the AVE8062 molecule and the feasibility of dynamic…
Expand
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
S. Cai
Recent Patents on Anti-Cancer Drug Discovery
2007
Corpus ID: 25873315
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and…
Expand
Highly Cited
2007
Highly Cited
2007
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
T. Kim
,
Murali K. Ravoori
,
+12 authors
A. Sood
Cancer Research
2007
Corpus ID: 25713952
The purpose of this study was to examine the therapeutic efficacy and underlying mechanisms of action of a vascular-disrupting…
Expand
Review
2004
Review
2004
Vascular Targeting Agents as Cancer Therapeutics
P. Thorpe
Clinical Cancer Research
2004
Corpus ID: 1739027
Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood…
Expand
Highly Cited
2003
Highly Cited
2003
Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis
K. Hori
,
Sachiko Saito
British Journal of Cancer
2003
Corpus ID: 1655418
We previously reported that a novel combretastatin A-4 derivative, AC7700, has remarkable antitumour effects because of an…
Expand
Review
2002
Review
2002
The biology of the combretastatins as tumour vascular targeting agents
G. Tozer
,
C. Kanthou
,
C. Parkins
,
S. Hill
International journal of experimental pathology…
2002
Corpus ID: 39870167
The tumour vasculature is an attractive target for therapy. Combretastatin A‐4 (CA‐4) and A‐1 (CA‐1) are tubulin binding agents…
Expand
Highly Cited
2002
Highly Cited
2002
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
K. Hori
,
S. Saito
,
K. Kubota
British Journal of Cancer
2002
Corpus ID: 16403726
In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and…
Expand
Highly Cited
1999
Highly Cited
1999
A Novel Combretastatin A‐4 Derivative, AC‐7700, Shows Marked Antitumor Activity against Advanced Solid Tumors and Orthotopically Transplanted Tumors
Y. Nihei
,
Y. Suga
,
+11 authors
T. Tsuruo
Japanese journal of cancer research : Gann
1999
Corpus ID: 13717321
AC‐7700, a novel combretastatin A‐4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE